CompletedPhase 2NCT00109928
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Studying Anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Daruka Mahadevan, MD, PhDUniversity of Arizona
- Intervention
- cisplatin(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2014
Study locations (30)
- Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Kaiser Permanente - Fremont, Fremont, California, United States
- Kaiser Permanente Medical Center - Hayward, Hayward, California, United States
- Kaiser Permanente Medical Center - Oakland, Oakland, California, United States
- South Sacramento Kaiser-Permanente Medical Center, Sacramento, California, United States
- Kaiser Permanente Medical Center - San Francisco Geary Campus, San Francisco, California, United States
- Kaiser Permanente Medical Center - Santa Teresa, San Jose, California, United States
- Kaiser Foundation Hospital - San Rafael, San Rafael, California, United States
- Kaiser Permanente Medical Center - Santa Clara Kiely Campus, Santa Clara, California, United States
- Kaiser Permanente Medical Center - Santa Rosa, Santa Rosa, California, United States
- Kaiser Permanente Medical Center - South San Francisco, South San Francisco, California, United States
- Kaiser Permanente Medical Facility - Stockton, Stockton, California, United States
- Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States
- Kaiser Permanente Medical Center - Walnut Creek, Walnut Creek, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00109928 on ClinicalTrials.govOther trials for Anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaCorvus Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT06494371A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06137144AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.AstraZeneca
- ACTIVE NOT RECRUITINGPHASE1NCT04526834Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaTessa Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT04881838CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCLChildren's Cancer Group, China
- ACTIVE NOT RECRUITINGPHASE2NCT02978625Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNational Cancer Institute (NCI)
- RECRUITINGNCT04220970Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) RegistryThe Lymphoma Academic Research Organisation